Biggest News Aggregation in the World

Page 3 - Rns Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rns Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rns Pharma Today - Breaking & Trending Today

NS Pharma Reports on Results of VILTEPSO® (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy

Published: October 24, 2022

/PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru...

Source: prnewswire.com

Related Topics:

VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference

Published: October 4, 2022

/PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru...

Source: prnewswire.com

Related Topics:

Tsugio Tanaka Toru Nakai Leslie Magnus Ns Pharma Inc Prnewswire Ns Pharma Inc Nippon Shinyaku Co Ltd World Muscle Society Nippon Shinyaku Vice President Priority Review Rare Pediatric Disease Orphan Drug Fast Track Conditional Early Approval Medical Information Rns Pharma

VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases

Published: May 31, 2022

/PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru...

Source: prnewswire.com

Related Topics:

United States Tsugio Tanaka Toru Nakai Leslie Magnus Ns Pharma Inc Prnewswire Ns Pharma Inc Nippon Shinyaku Co Ltd Nippon Shinyaku Term Functional Efficacy Duchenne Muscular Dystrophy Vice President Neuromuscular Diseases Priority Review Rare Pediatric Disease Orphan Drug Fast Track Conditional Early Approval Medical Information Rns Pharma

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

Published: January 25, 2022

/PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a...

Source: prnewswire.com

Related Topics:

United States New Jersey Linda Marb Tsugio Tanaka Toru Nakai Ns Pharma Inc Capricor Therapeutics Inc Nippon Shinyaku Co Ltd Drug Administration Corporate Communications Dept Nippon Shinyaku Capricor Therapeutics Orphan Drug Designation Regenerative Medicine Advanced Therapy Century Treatment Act Century Cures Act Communications Dept Rns Pharma

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

Published: January 25, 2022

/PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a...

Source: prnewswire.com

Related Topics:

Page 4 Page 5 Page 6 Page 7

Page 3 - Rns Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Rns Pharma Today - Breaking & Trending Today

NS Pharma Reports on Results of VILTEPSO&#xAE; (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy

VILTEPSO&#xAE; (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference

VILTEPSO&#xAE; (viltolarsen) injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

NS Pharma Reports on Results of VILTEPSO® (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy

VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference

VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases